{
    "clinical_study": {
        "@rank": "70596", 
        "arm_group": [
            {
                "arm_group_label": "Meganatural-Az Grapeseed Extract", 
                "arm_group_type": "Active Comparator", 
                "description": "Meganatural-Az\u00ae doses: 30mg / day for 2 weeks; 4 weeks of 600 mg/day, 4 weeks 1000mg / day"
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Subjects receive capsules identical in appearance to the active agent with the same incremental schedule"
            }
        ], 
        "brief_summary": {
            "textblock": "Alzheimer Disease (AD) is a progressive brain disease generally known as senile dementia.\n      Our proposed study will establish safety and pharmacokinetics of Meganatural-AZ GSPE in AD\n      subjects. As secondary measures, we will also provide the essential human data to guide the\n      design of future studies to test the efficacy of GSPE in mitigating cognitive deterioration\n      in AD patients."
        }, 
        "brief_title": "Phase 2 Study to Examine Grape Seed Extract as an Anti-Oligomerization Agent in Alzheimer's Disease (AD)", 
        "completion_date": {
            "#text": "November 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Alzheimer's Disease", 
        "condition_browse": {
            "mesh_term": "Alzheimer Disease"
        }, 
        "detailed_description": {
            "textblock": "This study aims to establish the safety and pharmacokinetics of Meganatural-Az\u00ae GSPE in\n      subjects with Alzheimer's disease. As a secondary goal, clinical and biomarker indices of\n      therapeutic efficacy will also be evaluated. The proposed study will provide the essential\n      human data necessary to guide the design of future studies testing the efficacy of GSPE in\n      mitigating cognitive deterioration in AD patients."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  NINCDS/ADRDA criteria for probable AD\n\n          -  MMSE between 12-26\n\n          -  Treatment with a cholinesterase inhibitor or an NMDA (N-methyl-D-asparate) antagonist\n             with stable dose for at least 12 weeks\n\n          -  Home monitoring available for supervision of medications\n\n          -  Caregiver available to accompany patient to all visits and willing to participate in\n             study as informant\n\n          -  Fluent in English or Spanish\n\n          -  Medical stability for this study as confirmed by review of records, internist's\n             physical exam, neurological exam, and laboratory tests\n\n          -  Stable doses of non-excluded medication\n\n          -  No evidence of hepatic insufficiency\n\n          -  Able to swallow oral medications\n\n          -  Ability to participate in the informed consent process\n\n        Exclusion Criteria:\n\n          -  History of hypotension or unstable hypertension\n\n          -  Active hepatic or renal disease\n\n          -  Use of another investigational drug within the past two months\n\n          -  History of clinically significant stroke\n\n          -  History of seizure or head trauma with disturbance of consciousness within the past\n             two years\n\n          -  Major mental illness including psychotic disorders, bipolar disorder, or major\n             depressive episode that is not in remission for less than 12 months\n\n          -  Women of child-bearing age unless using effective birth control or at least one year\n             post-menopausal or surgically menopausal\n\n          -  Any ferrous or metallic materials which are contraindicated for MRI\n\n        Medication Exclusions\n\n          -  Current use of drugs with significant anticholinergic or antihistaminic properties"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "N/A"
        }, 
        "enrollment": {
            "#text": "20", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "January 9, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02033941", 
            "org_study_id": "GCO 09-0307", 
            "secondary_id": [
                "5R21AT005510", 
                "HSM 10-00115"
            ]
        }, 
        "intervention": [
            {
                "arm_group_label": "Meganatural-Az Grapeseed Extract", 
                "description": "Meganatural-Az\u00ae doses: 30mg / day for 2 weeks; 4 weeks of 600 mg/day, 4 weeks 1000mg / day", 
                "intervention_name": "Meganatural-Az Grapeseed Extract", 
                "intervention_type": "Drug", 
                "other_name": [
                    "Grapeseed Polyphenolic Extract", 
                    "Grapeseed Phenol Extract", 
                    "GSPE"
                ]
            }, 
            {
                "arm_group_label": "Placebo", 
                "description": "Subjects receive capsules identical in appearance to the active agent with the same incremental schedule", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Grape Seed Extract"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Alzheimer's Disease", 
            "Grapeseed Extract", 
            "Clinical Trial", 
            "Meganatural-AZ", 
            "anti-oligomerization", 
            "Phase 2", 
            "Dietary Supplement", 
            "Nutraceutical"
        ], 
        "lastchanged_date": "January 9, 2014", 
        "link": {
            "description": "Center site", 
            "url": "http://mssm.edu/adrc"
        }, 
        "location": {
            "contact": {
                "email": "emily.exter@mssm.edu", 
                "last_name": "Emily Exter, BA", 
                "phone": "212-241-8329"
            }, 
            "contact_backup": {
                "email": "amanda.burden@mssm.edu", 
                "last_name": "Amanda Burden, BA", 
                "phone": "212-241-8329"
            }, 
            "facility": {
                "address": {
                    "city": "New York", 
                    "country": "United States", 
                    "state": "New York", 
                    "zip": "10029"
                }, 
                "name": "Mount Sinai Alzheimer's Disease Research Center"
            }, 
            "investigator": {
                "last_name": "Hillel T Grossman, MD", 
                "role": "Principal Investigator"
            }, 
            "status": "Not yet recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "Phase II Grape Seed Extract as Anti-Oligomerization Agent in Alzheimer's Disease", 
        "overall_contact": {
            "email": "emily.exter@mssm.edu", 
            "last_name": "Emily Exter, BA", 
            "phone": "212-241-8329"
        }, 
        "overall_contact_backup": {
            "email": "hillel.grossman@mssm.edu", 
            "last_name": "Hillel Grossman, MD", 
            "phone": "212-241-8329"
        }, 
        "overall_official": [
            {
                "affiliation": "Mount Sinai School of Medcine", 
                "last_name": "Hillel Grossman, MD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Mount Sinai School of Medicine", 
                "last_name": "Samuel Gandy, MD/PhD", 
                "role": "Principal Investigator"
            }
        ], 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "November 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "the pharmacokinetics and effects of Meganatural-Az\u00ae on tau and abnormally phosphorylated tau CSF concentrations", 
                "measure": "pharmacokinetic analysis", 
                "safety_issue": "Yes", 
                "time_frame": "up to 22 months"
            }, 
            {
                "description": "adverse effects reporting", 
                "measure": "primary safety evaluations", 
                "safety_issue": "Yes", 
                "time_frame": "up to 22 months"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02033941"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Mount Sinai School of Medicine", 
            "investigator_full_name": "Hillel Grossman", 
            "investigator_title": "Associate Professor", 
            "responsible_party_type": "Sponsor-Investigator"
        }, 
        "secondary_outcome": [
            {
                "description": "\u03b2-amyloid (A\u03b2) in plasma and in cerebral spinal fluid (CSF) specimens", 
                "measure": "AD Biomarkers", 
                "safety_issue": "No", 
                "time_frame": "up to 22 months"
            }, 
            {
                "description": "cognitive and functional assessments including the ADAS-cog, ADCS CGIC, MMSE, and ADL.", 
                "measure": "cognitive and functional assessments", 
                "safety_issue": "No", 
                "time_frame": "up to 22 months"
            }
        ], 
        "source": "Mount Sinai School of Medicine", 
        "sponsors": {
            "collaborator": {
                "agency": "National Center for Complementary and Alternative Medicine (NCCAM)", 
                "agency_class": "NIH"
            }, 
            "lead_sponsor": {
                "agency": "Hillel Grossman", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "January 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "January 2014"
    }
}